Sionna Therapeutics (NASDAQ:SION) Stock Rating Upgraded by Lifesci Capital

Sionna Therapeutics (NASDAQ:SION) was upgraded by research analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also commented on SION. Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Citigroup began coverage on shares of Sionna Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. BTIG Research reiterated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. Finally, Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $47.63.

Sionna Therapeutics Price Performance

Shares of SION opened at $38.00 on Wednesday. The firm has a market capitalization of $1.70 billion and a PE ratio of -7.80. The company’s fifty day moving average price is $39.89 and its 200-day moving average price is $34.81. Sionna Therapeutics has a 1-year low of $7.26 and a 1-year high of $45.00.

Insider Buying and Selling at Sionna Therapeutics

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares in the company, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 382,368 shares of company stock valued at $15,898,607 over the last quarter. 3.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SION. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics in the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics during the second quarter worth about $31,000. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics during the fourth quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $45,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $58,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.